Search research articles
Contact Us
Filters
Showing results (11-20 of 134) with videos related to
Page
of 14
Sort By:
Expert Opinion on Pharmacotherapy
|
February 26, 2013
Trametinib (GSK1120212) in the treatment of melanoma
April K S Salama, Kevin B Kim
Current Oncology Reports
|
August 27, 2013
MEK inhibition in the treatment of advanced melanoma
April K S Salama, Kevin B Kim
Expert Opinion on Drug Safety
|
June 27, 2013
Drug safety evaluation of vemurafenib in the treatment of melanoma
Kenneth Y Tsai, Sasan Nowroozi, Kevin B Kim
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|
April 24, 2014
Dabrafenib
Radhika Kainthla, Kevin B Kim, Gerald S Falchook
Pharmacogenomics and Personalized Medicine
|
February 12, 2014
Dabrafenib for treatment of BRAF-mutant melanoma
Radhika Kainthla, Kevin B Kim, Gerald S Falchook
Journal of Global Oncology
|
September 23, 2018
Case Report of a Pregnancy During Ipilimumab Therapy
Andrew Mehta, Kevin B Kim, David R Minor
The Journal of Clinical and Aesthetic Dermatology
|
May 28, 2013
Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib
Philip R Cohen, Agop Y Bedikian, Kevin B Kim
JCO Precision Oncology
|
February 25, 2026
Retrospective Study of Trametinib in Patients With Advanced <i>NF1</i>-Mutant Melanoma
Lin Wang, Mohammed Kashani-Sabet, Prasad Dighe, et al.
The Annals of Pharmacotherapy
|
November 22, 2013
Dabrafenib therapy for advanced melanoma
Van Anh Trinh, Jennifer E Davis, Jaime E Anderson, et al.
Melanoma Research
|
July 13, 2007
Use of sargramostim as maintenance therapy in patients with stage IV melanoma at high risk for systemic recurrence
Reena H Hemrajani, Kevin B Kim, Warren R Amos, et al.
Page
of 14
Search research articles
Search
Showing results (11-20 of 134) with videos related to
Sort By:
Page
of 14
Expert Opinion on Pharmacotherapy
|
February 26, 2013
Trametinib (GSK1120212) in the treatment of melanoma
April K S Salama, Kevin B Kim
Current Oncology Reports
|
August 27, 2013
MEK inhibition in the treatment of advanced melanoma
April K S Salama, Kevin B Kim
Expert Opinion on Drug Safety
|
June 27, 2013
Drug safety evaluation of vemurafenib in the treatment of melanoma
Kenneth Y Tsai, Sasan Nowroozi, Kevin B Kim
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|
April 24, 2014
Dabrafenib
Radhika Kainthla, Kevin B Kim, Gerald S Falchook
Pharmacogenomics and Personalized Medicine
|
February 12, 2014
Dabrafenib for treatment of BRAF-mutant melanoma
Radhika Kainthla, Kevin B Kim, Gerald S Falchook
Journal of Global Oncology
|
September 23, 2018
Case Report of a Pregnancy During Ipilimumab Therapy
Andrew Mehta, Kevin B Kim, David R Minor
The Journal of Clinical and Aesthetic Dermatology
|
May 28, 2013
Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib
Philip R Cohen, Agop Y Bedikian, Kevin B Kim
JCO Precision Oncology
|
February 25, 2026
Retrospective Study of Trametinib in Patients With Advanced <i>NF1</i>-Mutant Melanoma
Lin Wang, Mohammed Kashani-Sabet, Prasad Dighe, et al.
The Annals of Pharmacotherapy
|
November 22, 2013
Dabrafenib therapy for advanced melanoma
Van Anh Trinh, Jennifer E Davis, Jaime E Anderson, et al.
Melanoma Research
|
July 13, 2007
Use of sargramostim as maintenance therapy in patients with stage IV melanoma at high risk for systemic recurrence
Reena H Hemrajani, Kevin B Kim, Warren R Amos, et al.
Page
of 14